Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study

作者：Damien Fournier, Romain Carrière, Maxime Bour, Emilie Grisot, Pauline Triponney, Cédric Muller, Jerome L. Lemoine, Katy Jeannot, Patrick Plésiat, the GERPA Study Group · 发表于：Antimicrobial Agents and Chemotherapy · 年份：2020 · DOI：10.1128/aac.01117-20 · 被引用次数：71 · 研究领域：Antibiotic Resistance in Bacteria、Antibiotics Pharmacokinetics and Efficacy、Pneumonia and Respiratory Infections

Resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam (C/T) were assessed on a collection of 420 nonredundant strains nonsusceptible to ceftazidime (MIC > 8 μg/ml) and/or imipenem (>4 μg/ml), collected by 36 French hospital laboratories over a one-month period (the GERPA study). Rates of C/T resistance (MIC > 4/4 μg/ml) were equal to 10% in this population (42/420 strains), and 23.2% (26/112) of the isolates were resistant to both ceftazidime and imipenem.